Effect of renal impairment on disposition of pentopril and its active metabolite.
Disposition of pentopril was studied in 15 male volunteers with varying renal functions. Mild to moderate compromise in renal function did not demonstrate any appreciable changes in plasma concentration of pentopril, the prodrug ester of the active angiotensin-converting enzyme (ACE) inhibitor CGS 13934. This is consistent with the known elimination pattern for pentopril, which is eliminated primarily by hydrolysis to the active inhibitor. In contrast, the plasma concentration of the active ACE inhibitor was sensitive to moderate changes in renal function. Because of the reciprocal relationship of AUC and clearance, AUC did not change to any appreciable extent until creatinine clearance (CLCR) dropped to about 50 ml/min. Below 50 ml/min of CLCR, AUC and half-life increased sharply with reduced kidney function. Because of the significant contribution of the renal secretion process to total renal elimination of both pentopril and the active metabolite, prediction of renal clearance from CLCR was poor at relatively normal kidney function (CLCR greater than 80 ml/min). However, renal secretory clearances for both pentopril and metabolite were well correlated to p-aminohippuric acid clearance. In patients with moderately compromised renal function (glomerular filtration rate less than 40 ml/min), tubular secretion rate of creatinine approaches its glomerular filtration rate and hence CLCR could be used as a predictor of renal clearance and other disposition parameters. Plasma ACE activity also demonstrated prolonged inhibition with decreased renal function. Based on the prolonged blockade of plasma ACE activity, some correction in dose or dosing interval is anticipated in patients with moderately compromised renal function (CLCR less than 50 ml/min).
Rakhit
A
A
Pharmaceuticals Division, Ciba-Geigy Corp., Summit, NJ 07901.
Radensky
P
P
Szerlip
H M
HM
Kochak
G M
GM
Audet
P R
PR
Hurley
M E
ME
Feldman
G M
GM
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics*; D003404:Creatinine / Q000378:metabolism; D005919:Glomerular Filtration Rate; D006801:Humans; D007211:Indoles / Q000493:pharmacokinetics*; D007674:Kidney Diseases / Q000378:metabolism*; D007684:Kidney Tubules / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010130:p-Aminohippuric Acid / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C038810:CGS 13945; D003404:Creatinine; D010130:p-Aminohippuric Acid